Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

endpoints include duration of response, progression-free survival and overall survival.

Owen A. O'Connor, MD, PhD, Director, Lymphoid Development & Malignancy Program and Chief, Lymphoma Service, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, is the international study chair.

In accordance with the PROPEL study design, in January 2007, the DMC completed an interim analysis of safety data based on the first 10 patients enrolled to the study who completed at least one cycle of treatment with PDX, and recommended that the trial continue per the protocol. Also in accordance with the study design, in September 2007, an interim analysis of patient response and safety data was conducted based on the first 35 patients enrolled to the study who completed at least one cycle of treatment with PDX. The results of the interim analysis of patient response data exceeded the pre-specified threshold for continuation of the trial, which required a minimum of four responses (complete or partial) out of the first 35 evaluable patients, as determined by independent oncology review. In addition, the DMC identified no major safety concerns and recommended that the trial continue per the protocol.

The PROPEL trial is being conducted under an agreement with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process. The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of an NDA, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA. The FDA granted orphan drug designation to PDX for the treatment of T-cell lymphoma in July 2006 and granted fast track designation to PDX for the treatment of patients with T-cell lymphoma in September 2006. In April 2007, the Commission of the European Communities, with a favorable opinion of the Comm
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... data demonstrates that flibanserin, a novel, non-hormonal medicine being ... dysfunction, Hypoactive Sexual Desire Disorder (HSDD), does not impair ... when taken at bedtime. The data was presented at ... (SMSNA) 20th Annual Fall Scientific Meeting in ... accepted this study as a late breaking abstract for ...
(Date:11/22/2014)... Nov. 21, 2014 Statistics released from a ... driving increase astronomically during the holidays, beginning with Thanksgiving ... cities. The data, highlighted in ... as part of their annual Sober Days ... picture of high-risk drinking and increased rates of DUI ...
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
Breaking Medicine Technology:Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3Alarming Stats Show Holiday Drinking an Issue for Many 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... Sept. 8 Silence Therapeutics plc (AIM: SLN) ("Silence" ... patents by the United States Patent and Trademark Office ... RNA (siRNA) sequences against the validated cancer targets epidermal ... growth factor receptor 1 (VEGFR1).  EGFR-RP and VEGFR1 have ...
... -- POINT RICHMOND, Calif., Sept. 7 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Medicine Technology:Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics 2Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics 3Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics 4Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 2Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 3Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 4Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 5Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 6Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010 7
(Date:11/23/2014)... 2014 iFitDress.com, a well-known wedding dress manufacturer, ... gowns . They are now offered at deeply discounted ... last from now to Dec. 15. The main purpose of ... the company’s high quality items are ideal options for ladies ... sum of money. All its new mint cocktail dresses are ...
(Date:11/23/2014)... TX (PRWEB) November 23, 2014 ... Devices Market 2006 to 2020 - Asia-Pacific” provides ... energy devices market segments: minimally invasive body contouring ... devices. The analysis includes market size data by ... for the following countries: China, Japan, South Korea, ...
(Date:11/23/2014)... 23, 2014 Pro Ace Care, a renowned ... will now be providing an 8 year warranty on its ... tank installations went up due to the impending winter season, ... customers of the premium service that the company provides. As ... warranty on John Wood and Bradford hot water tanks. ...
(Date:11/23/2014)... 21, 2014 (HealthDay News) -- Close friends have more ... group does, a new study says. "We,ve ... have an influence on individual alcohol use, but there ... peer group and the friend group,s influence on those ... School of Public Health, said in a university news ...
(Date:11/23/2014)... 2014 Locks-Magnetic.com, a notable magnetic locks ... all the new products are available at low rates ... is proud of the new emergency doors. The emergency ... customers can choose from several colors. All of the ... emergency door release is not as easy as many ...
Breaking Medicine News(10 mins):Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Close Friends May Be Key to Teens' Drinking 2
... Institute of Health received over $100,000 from drug companies in ... to reports in a newspaper on Sunday. ,The actions ... year during an internal review, which concluded that he was ... according to reports from the Los Angeles Times. ,The ...
People who have a low response to alcohol or the so called ability to...
... gamblers have strong addiction to it.,"I'd say that there is ... I get from gambling," said one addict//. ,There ... thereby, creating more attraction for those with gambling problems. According ... the number of addicts. ,"It's related to other ...
... scientists have developed a new generation of antibiotics ... this approach bacteria has been rendered benign rather killed. ... bacteria in the light of several antibiotics losing their ... ,Tests have shown that these compounds actively blocked ...
... 10, sent a warning against dengue fever in the midst ... capital//. ,From this year’s January 1 to ... been reported, said the department. ,In order ... collaboration with the local officials of the affected areas, according ...
... A new survey has revealed that extreme and prolonged stress could ... could lead to grave health problems, a research has revealed.// ... sleep is a top worry for many, along with the rigors ... concerned with the bad effects of smoking or drinking, not even ...
Cached Medicine News:Health News:Medical researcher Accused of 'serious misconduct' 2Health News:Compulsive Gambling – a psychiatric disorde 2Health News:Latest Weapon in Battle against Drug-Resistant Bacteria 2Health News:‘Search and Destroy’ operation against dengue mosquitoes in Philippin 2
... 1/3 hp. 0-8 scfm/0-29.8 in.hg.@sea level. Incredibly ... to 4 collection canister systems at one ... changes during the procedure. Standard canister set-up ... filters not included). UL, c-UL and CE ...
... is a new term being used today to describe ... liquid fill that may have been used in silicone ... science, this is not new technology cohesive is ... the sticking together nature of the gel. All of ...
This Implant enhances and restores the nasal contour, The large selection of sizes with a variety of flares and lengths allows for more individualized results...
... designed to enhance the chin contour, this chin ... a high-profile central chin projection. Symmetrical Chin ... this implant provides a high central projection, as ... Cleft Chin Implants - Designed with a unique ...
Medicine Products: